Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

GRI Bio, Inc. Common Stock (GRI)

Pharmaceutical Preparations

https://www.gribio.com

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis.

2223 AVENIDA DE LA PLAYA, SUITE 208
LA JOLLA, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/24/2023

Market Cap

1,414,962

Shares Outstanding

4,520,000

Weighted SO

4,520,233

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

HOWL --.--%

EWTX --.--%

DBTX --.--%

CELC --.--%

CCCC --.--%

STTK --.--%

ELYM --.--%

PRLD --.--%

GLUE --.--%

Beta

-1.7959

Last Div

0.0000

Range

0.4-335.426

Chg

-0.0061

Avg Vol

481762

Mkt Cap

1414962

Exch

NASDAQ

Country

US

Phone

619 400 1170

DCF Diff

-2.5868

DCF

3.8868

Div Yield

0.0000

P/S

0.2623

EV Multiple

0.5549

P/FV

0.0469

Div Yield %

0.0000

P/E

-0.0267

PEG

0.0001

Payout

0.0000

Current Ratio

3.1065

Quick Ratio

3.1065

Cash Ratio

2.8669

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

25063.3333

CCC

-25063.3333

Gross Margin

0.9967

Op Margin

-1.5975

Pretax Margin

-1.5347

Net Margin

-1.5347

Eff Tax Rate

-0.1829

ROA

-1.1774

ROE

-3.3102

ROCE

-1.7896

NI/EBT

1.0000

EBT/EBIT

0.9607

EBIT/Rev

-1.5975

Debt Ratio

0.0064

D/E

0.0095

LT Debt/Cap

0.0000

Total Debt/Cap

0.0094

Int Coverage

0.0000

CF/Debt

-249.2222

Equity Multi

1.4899

Rec Turnover

0.0000

Pay Turnover

0.0146

Inv Turnover

0.0000

FA Turnover

36.6939

Asset Turnover

0.7672

OCF/Share

-24.5007

FCF/Share

-24.5007

Cash/Share

13.8790

OCF/Sales

-2.0792

FCF/OCF

1.0000

CF Coverage

-249.2222

ST Coverage

-249.2222

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

0.0469

P/B

0.0469

P/S

0.2623

P/E

-0.0267

P/FCF

-0.1262

P/OCF

-0.0197

P/CF

-0.0197

PEG

0.0001

P/S

0.2623

EV Multiple

0.5549

P/FV

0.0469

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Dec 05, 09:05 GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”) Seeking Alpha Dec 05, 00:10 The Fourth Quarter Started Slow, But It May Finish Strong GlobeNewswire Inc. Nov 27, 08:35 GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”) GlobeNewswire Inc. Oct 31, 08:45 GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases GlobeNewswire Inc. Oct 27, 09:15 AgriFORCE Regains Compliance with Nasdaq Continuing Listing Requirements

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
0.00 12/29/2008 11/30/-0001 11/30/-0001 11/30/-0001